Monovalent mRNA COVID-19 vaccines provide durable protection against critical outcomes COVID19vaccine mRNAvaccine COVID19prevention IVYnetwork publichealth CDC infectiousdiseases immunization healthresearch healthscience CDCMMWR
By Neha MathurMay 2 2023 In a recent Morbidity and Mortality Weekly Report published on the United States Center for Disease Control and Prevention website, researchers evaluated the durability of protection conferred by monovalent messenger ribonucleic acid coronavirus disease 2019 vaccines against invasive mechanical ventilation and in-hospital death during the period of the predominance of Omicron, i.e., between February 1, 2022, and January 31, 2023.
Since the beginning of the pandemic, over 1.13 million COVID-19–related deaths have occurred in the United States, with most among patients aged ≥65 years. Authorities recommended a bivalent mRNA booster for all individuals who had completed a primary COVID-19 vaccination series from September 1, 2022, onward and were at a higher risk of progression to severe disease. However, bivalent vaccination uptake remained low among adults aged ≥18 years, i.e.
They collected demographic and clinical patient data through electronic health record review, or patient/proxy interview, including IMV receipt and in-hospital death within 28 days of hospital admission. Study findings The number of enrollees with IMV or in-hospital mortality in the IVY Network between February 1, 2022, and January 31, 2023, was 6,354; however, the final analysis sample set had only 70% of 6354, i.e., 4,421 individuals, of which 362 were cases, and 4,059 were controls. The average age of all included patients was 64 years. Notably, ~91% of COVID-19 patients had one or more persistent health issues, and 20% had experienced COVID-19 at least once.
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Study identifies immune signature to predict severe COVID-19 in cardiovascular patientsStudy identifies immune signature to predict severe COVID-19 in cardiovascular patients COVID19 cardiovascular immunophenotyping diseaseprogression predictivesignature healthcare research SARSCoV2 pandemic publichealth medrxivpreprint uni_tue
Lire la suite »
Medicinal cannabis helps cancer pain - studyMore rigorous trials are needed to confirm the findings, the Canadian researchers say.
Lire la suite »
Harvard Study: Divesting From Coal Is More Beneficial Than Previously Thought | OilPrice.comHarvard professors have researched the positive effects on emissions from divesting from coal. The study found that if an existing source of funding is cut off for a coal enterprise, it will have an extremely difficult time securing a new line of funding.
Lire la suite »
How good your high school was affects your cognition 60 years later, US study findsGoing to a higher quality high school could make a difference to your memory and language skills in later life, a new study indicates.
Lire la suite »
Cycling infrastructure needs to be built with women in mind, study suggests'It's about planning for the trips that aren't taken as well as those that are': Cycling infrastructure needs to be built with women in mind, study suggests cycling
Lire la suite »
Study: OpenAI's ChatGPT and GPT-4 'memorized' these booksOpenAI's ChatGPT may face a copyright quagmire after 'memorizing' these books
Lire la suite »